Treatment Issues: Newsletter of Experimental AIDS Therapies - Volume 15, Number 5, May 2001

The recent publication of HIV/AIDS Clinical Trials: A Directory for New York State by the Community Research Initiative on AIDS (CRIA) is something of a revelation. Measured by sheer quantity, HIV research is thriving, with 126 clinical trials listed at sites throughout New York, including trials accessible to New Yorkers being conducted in Connecticut, New Jersey, Philadelphia, and at the National Institutes of Health (NIH) campus in Bethesda, Maryland (which pays airfare).

This comprehensive directory is designed for ease of use, with one trial listed per page in a clear and consistent format. The key drug or condition being studied is stated prominently at the top of each page. Broad inclusion criteria are highlighted — previous treatment experience, CD4 count and viral load — along with a brief description of the trial's design and duration.

More complete entry criteria are detailed separately followed by a list of study sites, contact names and phone numbers. The directory is available without charge to people living with HIV and service providers.

To obtain copies, contact:
Community Research Initiative on AIDS (CRIA)
230 West 38th Street, 17th Floor
New York, NY 10018

212/924-3934, ext. 123

www.criany.org

What is being studied?

This directory provides an interesting snapshot of the kinds of HIV/AIDS research ongoing in this country. Here's a brief analysis of what's being studied with a few highlights:

• Pediatric trials represent 25% of the listed trials. (In the chart below right, pediatric trials are grouped together and include anti-HIV treatments, immune therapies and treatments for associated infections and conditions in children.)
• Of trials for anti-HIV treatments in adults, nearly half are for approved drugs; with a third investigating nine new treatments at various pre-approval stages. Overall, 10% of the 126 trials are for new drug treatments.
• About a quarter of adult trials are studying treatment management strategies such as treatment interruption and intensification.
• A surprising number of trials (see chart below left) are early phase safety and efficacy studies of new agents for treating HIV or its opportunistic infections.

What HIV CLinical Research is Available to New Yorkers?

20010510
GM150505

Copyright © 2001 - Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, Inc. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011  fredg@gmhc.org  http://www.gmhc.org

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990, 2001. AEGiS & the Sisters of Saint Elizabeth of Hungary. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS and the Sisters of Saint. Elizabeth of Hungary, or the party credited as the provider of the content.